OBJECTIVE: To probe into the application effect of optimized treatment 3 HLZE/4 HR regimen on patients with chronic viral hepatitis C complicated with tuberculosis. METHODS: A total of 80 patients with chronic viral hepatitis C complicated with tuberculosis admitted into this hospital from Jan. 2018 to Jan. 2020 were selected as subjects

the clinical data was retrospectively analyzed

and the patients were divided into sequential treatment group（group A） and combined treatment group（group B） according to different treatment regimens

with 40 cases in each group. Group A was given standard 2 HRZE/4 HR regimen

and group B was given 3 HLZE/4 HR regimen. The course of treatment

treatment completion rate

incidence of liver injury

incidence of drug resistance and overall cost of treatment were compared between two groups. RESULTS: The treatment completion rate of group B was 97.50%（39/40）

significantly higher than that of group A（85.00%

34/40）; the incidence of liver injury and drug resistance in group B were respectively 5.00%（2/40） and 2.50%（1/40）

significantly lower than those of group A（20.00%

8/40; 17.50%

7/40）; the overall cost of treatment in group B was（20.5±4.3） thousand yuan

significantly lower than（37.8±3.2） thousand yuan of group A; the course of treatment of group B was（7.13±2.05） months

significantly shorter than（9.34±2.46） months of group A

with statistically significant differences（P<0.05）. CONCLUSIONS: Both the standard 2 HRZE/4 HR regimen and the 3 HLZE/4 HR regimen are valuable in the treatment of patients with chronic viral hepatitis C combined with tuberculosis

but the 3 HLZE/4 HR regimen has better therapeutic efficacy and can reduce the incidence of liver injury and drug resistance in patients.